MAVACAMTEN: A door that has opened in the treatment of Hypertrophic Cardiomyopathy

被引：1
|
作者：
Hameed, Ishaque [1 ]
Siddiqui, Omer Mustafa [1 ]
Samad, Syed Abdus [2 ]
机构：
[1] Dow Univ Hlth & Sci, Civil Hosp, Dept Internal Med, Karachi, Pakistan
[2] Dow Univ Hlth & Sci, Civil Hosp, Dept Gen Surg, Karachi, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2023年 / 73卷 / 02期
关键词：
D O I：
10.47391/JPMA.7258
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [31] IMPACT OF GENOTYPE ON MAVACAMTEN RESPONSIVENESS IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
    Giudicessi, John
    Alsidawi, Said
    Geske, Jeffrey Benjamin
    Newman, Darrell Brian
    Arruda-Olson, Adelaide Maria
    Bos, Johan Martijn
    Ommen, Steve R.
    Ackerman, Michael John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 735 - 735
  • [32] The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
    Edelberg, Jay M.
    Sehnert, Amy J.
    Mealiffe, Matthew E.
    Del Rio, Carlos L.
    McDowell, Robert
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (05) : 497 - 510
  • [33] Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use
    Tina Nie
    Yahiya Y. Syed
    Drugs & Therapy Perspectives, 2023, 39 : 223 - 231
  • [34] Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
    Dong, Tiffany
    Alencherry, Ben
    Ospina, Susan
    Desai, Milind Y.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 1097 - 1106
  • [35] Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients
    Zatorski, Nicole
    Sobie, Eric A.
    Schlessinger, Avner
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (05) : 318 - 319
  • [36] MARVELOUS MAVACAMTEN: EXPLORING PHARMACOLOGICAL IMPROVEMENT OF HYPERTROPHIC CARDIOMYOPATHY
    Candelario, Isabel Rodriguez
    Roman-Ramos, Jose
    Polo, Francisco Tirado
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 3189 - 3189
  • [37] Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use
    Nie, Tina
    Syed, Yahiya Y.
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (07) : 223 - 231
  • [38] The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
    Jay M. Edelberg
    Amy J. Sehnert
    Matthew E. Mealiffe
    Carlos L. del Rio
    Robert McDowell
    American Journal of Cardiovascular Drugs, 2022, 22 : 497 - 510
  • [39] Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
    Davis, Bryton J.
    Volk, Hailey
    Nguyen, Olives
    Kamna, Daniel
    Chen, Hongya
    Barriales-Villa, Roberto
    Garcia-Pavia, Pablo
    Olivotto, Iacopo
    Owens, Anjali T.
    Coats, Caroline J.
    Abraham, Theodore P.
    Solomon, Scott D.
    Maron, Martin S.
    Masri, Ahmad
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (06):
  • [40] COST-EFFECTIVENESS OF MAVACAMTEN FOR THE TREATMENT OF PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN THE NETHERLANDS
    Buisman, L.
    Treur, M.
    Verkaik, M.
    Van De Wetering, G.
    Pronk, L. M.
    Pompen, M.
    Hurst, M.
    VALUE IN HEALTH, 2023, 26 (12) : S110 - S110
12345